Oliveira Manoel Domingos C, Alvares Juliana, Moreira Maria Consolação V
Hospital Felicio Rocho, Belo Horizonte, MG, Brasil.
Arq Bras Cardiol. 2010 Apr;94(4):527-34. doi: 10.1590/s0066-782x2010005000013. Epub 2010 Mar 26.
The slight increase in cardiac troponin in the blood of patients with heart failure (HF) suggests that myofibrils are degraded in the myocardium and released in the circulation, reflecting a continuous and progressive injury process in the contractile system.
To correlate the serum levels of cardiac troponin T (TnT) at the hospital admission of patients with decompensated HF and prognosis.
A total of 79 consecutive patients, hospitalized due to decompensated HF, with LVEF < 45%, were included in the study. Patients were followed for 8 months. We excluded patients using intravenous inotropic agents, as well as those with acute coronary syndrome, pulmonary thromboembolism, creatinine levels > 2.5 mg%, liver failure, or neuromuscular diseases.
High levels of TnTc (>0.02 ng/ml) were detected in 37 patients (46.84%). The global mortality was 35.4%. In the groups with high TnT and low TnT levels (<0.02 ng/ml) there were, respectively, 19 versus 9 deaths (RR=2.4; 95%CI 1.24-4.63; p=0.011), 5 versus 4 heart transplants (RR=1,42; 95%CI 0.41-4.89; p=0.73), 11 versus 7 patients needed IV inotropic agents (RR=1.78; 95%CI 0.77-4.12; p=0.26) and 14 versus 10 patients were re-hospitalized (RR=1.85; 95%CI 0.95-3.6; p=0.10). Mean troponin levels were significantly higher in those individuals who died (0.071+/-0,119 vs 0.032+/-0.046; p=0.004). At the multivariate analysis, the persistence of the third sound and the need for IV inotropic agents showed to be independent predictors of death; however, we observed a higher tendency towards mortality for patients presenting high TnT when compared to those with low troponin levels (HR=2.64; 95%CI 0.91-7.63; p=0.07).
The single troponin measurement at hospital admission in patients with decompensated HF predicts adverse outcomes and should be considered at the early stratification of long-term morbimortality.
心力衰竭(HF)患者血液中心肌肌钙蛋白略有升高,提示心肌中的肌原纤维发生降解并释放到循环中,反映了收缩系统持续进展的损伤过程。
探讨失代偿性HF患者入院时血清心肌肌钙蛋白T(TnT)水平与预后的关系。
本研究共纳入79例因失代偿性HF住院、左心室射血分数(LVEF)<45%的患者。对患者进行8个月的随访。我们排除了使用静脉注射正性肌力药物的患者,以及患有急性冠状动脉综合征、肺血栓栓塞、肌酐水平>2.5mg%、肝功能衰竭或神经肌肉疾病的患者。
37例患者(46.84%)检测到高水平的TnTc(>0.02ng/ml)。总死亡率为35.4%。TnT水平高和低(<0.02ng/ml)的组中,分别有19例和9例死亡(相对危险度[RR]=2.4;95%可信区间[CI]1.24 - 4.63;p=0.011),5例和4例接受心脏移植(RR=1.42;95%CI 0.41 - 4.89;p=0.73),11例和7例患者需要静脉注射正性肌力药物(RR=1.78;95%CI 0.77 - 4.12;p=0.26),14例和10例患者再次住院(RR=1.85;95%CI 0.95 - 3.6;p=0.10)。死亡患者的肌钙蛋白平均水平显著更高(0.071±0.119 vs 0.032±0.046;p=0.004)。多因素分析显示,第三心音持续存在和需要静脉注射正性肌力药物是死亡的独立预测因素;然而,与肌钙蛋白水平低的患者相比,TnT水平高的患者死亡倾向更高(风险比[HR]=2.64;95%CI 0.91 - 7.63;p=0.07)。
失代偿性HF患者入院时单次肌钙蛋白测量可预测不良预后,应在长期疾病死亡率的早期分层中予以考虑。